- Market Capitalization, $K 986,420
- Shares Outstanding, K 31,820
- Annual Sales, $ 6,020 K
- Annual Income, $ 92,080 K
- 60-Month Beta 2.06
- Price/Sales 172.42
- Price/Cash Flow 10.81
- Price/Book 4.94
|Period||Period Low||Period High||Performance|
| || |
-0.28 (-0.90%)since 11/12/19
| || |
+7.33 (+30.76%)since 09/12/19
| || |
+17.98 (+136.42%)since 12/12/18
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), today announced the appointment...
As of late, it has definitely been a great time to be an investor Zealand Pharma.
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is...
Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.
Boehringer Ingelheim and Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which...
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Apergy Corporation (NYSE:APY), vTv...
--- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway -
Company announcement - No. 03 / 2019